

FOR IMMEDIATE RELEASE

## **TherapeuticsMD featured at the 10<sup>th</sup> European Congress on Menopause and Andropause**

**MADRID, May, 21, 2015** — TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, will make multiple presentations and host a symposium highlighting the company's late-stage clinical candidates at the 10<sup>th</sup> European Congress on Menopause and Andropause being held May 20-22 in Madrid.

Dr. Sebastian Mirkin, TherapeuticsMD Chief Medical Officer, and its co-founder and Chief Clinical Officer, Dr. Brian Bernick, will provide the European menopausal community a comprehensive overview of the company's two late-stage investigational drugs Friday, May 22. Dr. Mirkin will discuss TX-001HR, the first-ever 17 $\beta$  estradiol and natural progesterone combination, which is currently in the phase 3 Replenish Trial for the treatment of vasomotor symptoms. Dr. Bernick will discuss TX-004HR, the company's investigational solubilized vaginal estradiol in the VagiCap<sup>TM</sup> softgel dosage form, currently in the phase 3 Rejoice Trial.

"We are excited to share with the European clinical community the progress and potential of TX-001HR and TX-004HR, our two late-stage investigational drugs," Dr. Mirkin said.

Dr. Mirkin also will conduct an oral presentation, "Vaginal Physical Examination Correlates with Vaginal Epithelial Cells and pH and Can be Used to Assess Treatment Efficacy of Vulvar and Vaginal Atrophy (VVA) with a novel 10 mcg Vaginal Gelcap (VagiCap<sup>TM</sup>)."

In addition, TherapeuticsMD presented two poster presentations of new data from a market survey of hormone therapy (HT) use among European women: "Behaviors/Attitudes Towards Hormone Replacement Therapy (HRT) Treatment for Menopausal Women in 5 Major European Countries" and "Factors Influencing Treatment Decisions Among Menopausal Women in 5 European Countries."

"While we report menopausal trends in Europe, menopause is not limited to women of any one country. It affects millions of women worldwide," Dr. Bernick said. "We take great pride in working to provide women around the world safer and more effective treatment options."

Hosted by the European Menopause and Andropause Society (EMAS), the EMAS Congress is a triennial gathering of specialty doctors, allied health professionals and researchers.

### **About TherapeuticsMD, Inc.**

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its patented SYMBODA<sup>TM</sup> technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company's clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD<sup>®</sup> and BocaGreenMD<sup>®</sup> brands. More information is available at the following websites: [www.therapeuticsmd.com](http://www.therapeuticsmd.com), [www.vitamedmd.com](http://www.vitamedmd.com), [www.vitamedmdrx.com](http://www.vitamedmdrx.com) and [www.bocagreenmd.com](http://www.bocagreenmd.com).

###

Contacts:

Dan Cartwright  
Chief Financial Officer  
561-961-1900  
Dan.Cartwright@TherapeuticsMD.com

Julia Amadio  
Chief Product Officer  
561-961-1900  
Julia.Amadio@TherapeuticsMD.com